Trials / Completed
CompletedNCT03952143
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 628 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 2 diabetes (T2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY900014 | Administered SC |
| DRUG | Insulin Lispro | Administered SC |
| DRUG | Insulin Glargine | Administered SC |
| DRUG | Insulin Degludec | Administered SC |
Timeline
- Start date
- 2019-05-27
- Primary completion
- 2021-01-20
- Completion
- 2021-01-20
- First posted
- 2019-05-16
- Last updated
- 2022-02-08
- Results posted
- 2022-02-08
Locations
41 sites across 3 countries: Argentina, China, Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03952143. Inclusion in this directory is not an endorsement.